Cidara Therapeutics reports Q2 EPS (14c), consensus (13c)

Reports Q2 revenue $7.6M, consensus $11.55M. “This quarter we made important progress in the advancement of our Cloudbreak drug-Fc conjugate DFC platform,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Most recently, we received Fast Track designation for CD388, which is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults who are at high-risk of severe influenza. Moreover, we continue to generate compelling data from ongoing preclinical studies of CD421, a CD73-targeting DFC, and our first oncology product candidate, which we intend to present at future scientific conferences.” Dr. Stein continued, “Looking ahead, we anticipate filing an Investigational New Drug Application in 2024 for CD421, a potential first-in-class inhibitor of CD73. We look forward to providing further data from our promising Cloudbreak programs at our planned R&D Day in the second half of this year.”